HuCAL® Recombinant Monoclonal Antibody Generation Service
Assays supporting SARS-CoV-2 vaccine, therapeutic, and diagnostic test development must be robust, scalable, and transferable to laboratories worldwide. They need to be designed and validated rapidly, yet without compromising quality.
We understand that critical antibody reagents for these vital assays must be highly specific for the chosen antigen, produced to a consistent quality, and easily available for scale-up according to demand. Bio-Rad’s custom HuCAL® antibody generation service can satisfy these needs, providing trustworthy antibodies, and overcoming the challenges of antibody generation using immunization of animals.
Our recombinant antibodies are selected from the fully synthetic, naïve Human Combinatorial Antibody Libraries (HuCAL) using a proprietary method of phage display. Our latest innovation introduces SpyTag technology to the platform, to build antibodies from modules by protein ligation, and perform site-directed conjugation.
This innovative combination of HuCAL and SpyTag technologies brings you:
*A Fast Track service for antibody generation in as little as 4 weeks is available subject to feasibility.
Our custom antibody experts are already working with global biopharma and diagnostic companies developing COVID-19 treatments and tests, providing them with custom antibodies as ELISA capture and detection reagents, and serological controls in human IgG, IgM, and IgA isotypes.
Take the next steps to source custom HuCAL antibodies for your SARS-CoV-2 assay development.
Our custom antibody laboratory in Neuried, Germany has passed an external risk assessment audit and is accredited with an official occupational safety standard for COVID-19.
Learn how our high-throughput generation process
addressed the need for rapid delivery of customized
antibodies during the COVID-19 pandemic.